The identification of these accessible regions within the KRAS protein structure may herald significant expansion of the therapeutic target landscape and provide a greater range of pharmacological interventions aimed at inhibiting KRAS-driven cellular proliferation within tumor settings. Here, KRAS is linked to neoplasm.